Gastric Aspirate Phosphatidylcholine Species in Preterm Neonates Receiving Aerosolized Surfactant

J Pediatr. 2023 Dec:263:113638. doi: 10.1016/j.jpeds.2023.113638. Epub 2023 Jul 29.

Abstract

Objective: To characterize phosphatidylcholine (PC) molecular species in serial gastric aspirates as biomarkers for lung maturity, delivery of aerosolized surfactant (AS), and need for intubation.

Methods: In a phase II clinical trial of aerosolized surfactant in preterm neonates with respiratory distress syndrome receiving noninvasive ventilation, infants received a maximum of 2 doses of nebulized beractant. Gastric aspirates were collected before and after each dose and were analyzed for PCs using liquid chromatography mass spectrometry.

Results: Of 149 infants enrolled, gastric aspirates were obtained before (n = 91) and after (n = 94) dose 1, and before (n = 56) and after (n = 57) dose 2 of nebulized beractant. The mean ± SD values of birthweight, gestational age, and age at collection of baseline gastric aspirate were 1.7 ± 0.6 kg, 31.7 ± 2.8 weeks, and 5.5 ± 1.7 hours, respectively. The most abundant PC in beractant and gastric aspirates was PC(16:0/16:0). Advancing gestational age and number of antenatal corticosteroid doses predicted increased gastric aspirate PC(16:0/16:0), whereas maternal diabetes predicted a decrease. Several PCs increased significantly (P < .05) after nebulized beractant, consistent with effective aerosol delivery. Infants who received intubation within 72 hours of birth were more likely to have lower PC(16:0/16:0) levels in baseline gastric aspirates compared with those who did not (P = .024).

Conclusions: PC molecular species in gastric aspirates of preterm neonates are potentially novel and precise biomarkers to assess lung maturity, aerosol delivery, and need for endotracheal intubation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Lipoproteins
  • Phosphatidylcholines / therapeutic use
  • Pregnancy
  • Pulmonary Surfactants* / therapeutic use
  • Respiratory Aerosols and Droplets
  • Respiratory Distress Syndrome, Newborn* / drug therapy
  • Surface-Active Agents / therapeutic use

Substances

  • Surface-Active Agents
  • Phosphatidylcholines
  • Pulmonary Surfactants
  • Lipoproteins
  • Biomarkers